CL2018000282A1 - Amida seleccionada de ácido gamma-hidroxibutírico y usos de la misma en el tratamiento de abuso de alcohol - Google Patents
Amida seleccionada de ácido gamma-hidroxibutírico y usos de la misma en el tratamiento de abuso de alcoholInfo
- Publication number
- CL2018000282A1 CL2018000282A1 CL2018000282A CL2018000282A CL2018000282A1 CL 2018000282 A1 CL2018000282 A1 CL 2018000282A1 CL 2018000282 A CL2018000282 A CL 2018000282A CL 2018000282 A CL2018000282 A CL 2018000282A CL 2018000282 A1 CL2018000282 A1 CL 2018000282A1
- Authority
- CL
- Chile
- Prior art keywords
- gamma
- treatment
- hydroxybutyric acid
- alcohol abuse
- selected amide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE RELACIONA CON UNA AMIDA SELECCIONADA DE ÁCIDO GAMMA-HIDROXIBUTÍRICO, UN PROCESO DE ELABORACIÓN Y USOS DE LOS MISMOS. LA INVENCIÓN TAMBIÉN INCLUYE UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UNA CANTIDAD EFICAZ DEL COMPUESTO SELECCIONADO DE LA INVENCIÓN PARA USARSE EN LA PREVENCIÓN O TRATAMIENTO DE ADICCIÓN A DROGAS, ESPECIALMENTE ABUSO O DEPENDENCIA AL ALCOHOL.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITUB2015A002860A ITUB20152860A1 (it) | 2015-08-04 | 2015-08-04 | Selezionata amide dell?acido ?-idrossibutirrico e suoi usi nel trattamento dell?abuso da alcool |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000282A1 true CL2018000282A1 (es) | 2018-07-13 |
Family
ID=54542363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000282A CL2018000282A1 (es) | 2015-08-04 | 2018-01-31 | Amida seleccionada de ácido gamma-hidroxibutírico y usos de la misma en el tratamiento de abuso de alcohol |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10336687B2 (es) |
| EP (1) | EP3331853B1 (es) |
| JP (1) | JP6832336B2 (es) |
| KR (1) | KR20180066033A (es) |
| CN (1) | CN108026029B (es) |
| AU (1) | AU2016302869B2 (es) |
| CA (1) | CA2994599C (es) |
| CL (1) | CL2018000282A1 (es) |
| CO (1) | CO2018002428A2 (es) |
| DK (1) | DK3331853T3 (es) |
| EA (1) | EA033769B9 (es) |
| ES (1) | ES2776628T3 (es) |
| GE (1) | GEP20207107B (es) |
| IL (1) | IL257314B (es) |
| IT (1) | ITUB20152860A1 (es) |
| MX (1) | MX2018001239A (es) |
| MY (1) | MY185942A (es) |
| PH (1) | PH12018550008A1 (es) |
| PL (1) | PL3331853T3 (es) |
| PT (1) | PT3331853T (es) |
| UA (1) | UA121994C2 (es) |
| WO (1) | WO2017021438A1 (es) |
| ZA (1) | ZA201801402B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110891564A (zh) * | 2017-07-31 | 2020-03-17 | 诺华股份有限公司 | 玛沃谷兰在减少酒精使用或在预防复用酒精中的用途 |
| US11878001B2 (en) | 2017-07-31 | 2024-01-23 | Novartis Ag | Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use |
| CN113185403A (zh) * | 2021-07-02 | 2021-07-30 | 山东国邦药业有限公司 | 一种甲醚制备环丙胺中间体环丙甲酸甲酯的方法 |
| WO2023126076A1 (en) * | 2022-01-03 | 2023-07-06 | Laboratorio Farmaceutico C.T. S.R.L. | Medical use of an amide of y-hydroxybutyric acid in the treatment of fragile x syndrome |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1283782B1 (it) * | 1996-08-09 | 1998-04-30 | Ct Lab Farm Srl | Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo |
-
2015
- 2015-08-04 IT ITUB2015A002860A patent/ITUB20152860A1/it unknown
-
2016
- 2016-08-03 MX MX2018001239A patent/MX2018001239A/es active IP Right Grant
- 2016-08-03 UA UAA201801726A patent/UA121994C2/uk unknown
- 2016-08-03 GE GEAP201614717A patent/GEP20207107B/en unknown
- 2016-08-03 PL PL16791313T patent/PL3331853T3/pl unknown
- 2016-08-03 KR KR1020187006231A patent/KR20180066033A/ko not_active Application Discontinuation
- 2016-08-03 EP EP16791313.6A patent/EP3331853B1/en active Active
- 2016-08-03 MY MYPI2018700405A patent/MY185942A/en unknown
- 2016-08-03 DK DK16791313.6T patent/DK3331853T3/da active
- 2016-08-03 EA EA201890419A patent/EA033769B9/ru not_active IP Right Cessation
- 2016-08-03 CN CN201680045364.9A patent/CN108026029B/zh active Active
- 2016-08-03 PT PT167913136T patent/PT3331853T/pt unknown
- 2016-08-03 ES ES16791313T patent/ES2776628T3/es active Active
- 2016-08-03 WO PCT/EP2016/068517 patent/WO2017021438A1/en active Application Filing
- 2016-08-03 CA CA2994599A patent/CA2994599C/en active Active
- 2016-08-03 JP JP2018502356A patent/JP6832336B2/ja active Active
- 2016-08-03 AU AU2016302869A patent/AU2016302869B2/en active Active
- 2016-08-03 US US15/750,047 patent/US10336687B2/en active Active
-
2018
- 2018-01-31 CL CL2018000282A patent/CL2018000282A1/es unknown
- 2018-02-01 IL IL257314A patent/IL257314B/en active IP Right Grant
- 2018-02-02 PH PH12018550008A patent/PH12018550008A1/en unknown
- 2018-02-28 ZA ZA2018/01402A patent/ZA201801402B/en unknown
- 2018-03-02 CO CONC2018/0002428A patent/CO2018002428A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GEP20207107B (en) | 2020-05-11 |
| UA121994C2 (uk) | 2020-08-25 |
| PH12018550008A1 (en) | 2018-07-09 |
| CN108026029A (zh) | 2018-05-11 |
| US10336687B2 (en) | 2019-07-02 |
| EA033769B1 (ru) | 2019-11-22 |
| MY185942A (en) | 2021-06-14 |
| AU2016302869B2 (en) | 2020-10-22 |
| MX2018001239A (es) | 2018-07-06 |
| ZA201801402B (en) | 2019-01-30 |
| EP3331853A1 (en) | 2018-06-13 |
| JP6832336B2 (ja) | 2021-02-24 |
| AU2016302869A1 (en) | 2018-03-15 |
| EP3331853B1 (en) | 2019-12-11 |
| CA2994599C (en) | 2023-08-29 |
| GEAP202014717A (en) | 2020-01-27 |
| CA2994599A1 (en) | 2017-02-09 |
| ES2776628T3 (es) | 2020-07-31 |
| IL257314B (en) | 2020-04-30 |
| BR112018002245A2 (pt) | 2018-09-18 |
| US20180230086A1 (en) | 2018-08-16 |
| WO2017021438A1 (en) | 2017-02-09 |
| ITUB20152860A1 (it) | 2017-02-04 |
| EA033769B9 (ru) | 2020-04-10 |
| JP2018523644A (ja) | 2018-08-23 |
| PL3331853T3 (pl) | 2020-06-15 |
| DK3331853T3 (da) | 2020-03-16 |
| KR20180066033A (ko) | 2018-06-18 |
| CN108026029B (zh) | 2020-12-04 |
| PT3331853T (pt) | 2020-02-25 |
| EA201890419A1 (ru) | 2018-07-31 |
| CO2018002428A2 (es) | 2018-07-10 |
| IL257314A (en) | 2018-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017003459A1 (es) | Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| ECSP19043710A (es) | Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas | |
| SV2018005771A (es) | Derivados de piridiniltriazol sustituidos con amida y usos de estos | |
| CL2018001705A1 (es) | Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante. | |
| CL2018000223A1 (es) | Combinación de antagonista de pd-1 con un inhibidor de egfr | |
| CL2018000542A1 (es) | Nuevos derivados de fenoximetilo. | |
| GT201600070A (es) | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CR20160275A (es) | Derivados del sulphamoylpyrrolamide y uso como medicamento para el tratamiento de la hepatitis b | |
| CL2018001226A1 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| CL2017001046A1 (es) | Inhibidoes del bromodominio | |
| CL2018000282A1 (es) | Amida seleccionada de ácido gamma-hidroxibutírico y usos de la misma en el tratamiento de abuso de alcohol | |
| DOP2016000253A (es) | Nuevos compuestos | |
| BR112017008481A2 (pt) | composto antimicótico | |
| MX2022001796A (es) | Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. | |
| BR112017024908A2 (pt) | usos terapêuticos da 4-cloroquinurenina | |
| DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| CO2017001076A2 (es) | Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam | |
| CO2019007671A2 (es) | Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer | |
| BR112019000240A2 (pt) | composições farmacêuticas | |
| UY37166A (es) | Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano | |
| EA201791483A1 (ru) | Фармацевтическая композиция для лечения микоза | |
| MX2020004731A (es) | Terapias de combinacion de inhibidor ezh2. | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
| CO2016001336A1 (es) | Método y composición y kit para tratar la disfunción eréctil |